Istaroxime

DB06157InvestigationalSmall molecule

Investigated for use/treatment in heart disease.

Mechanism: Reduces the sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function.
Curator reviewed
Primary indication: Investigated for use/treatment in heart disease.Curator reviewed
Formula / weight: C₂₁H₃₂N₂O₃ · 360.498 g/mol (avg)
Code names: PST-2744 · ST-2744

Resolves to

Compound

Structure

InChIKeyMPYLDWFDPHRTEG-IFVNMTGRSA-NSMILES[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC(=O)[C@@]2([H])CC(CC[C@]12C)=NOCCN

Targets

What you can answer from here — as of August 30, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Istaroxime, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.